Passage Bio, Inc. (PASG) is a clinical-stage genetic-medicines company that has spent 2026 transforming itself. After winding down its AAV (adeno-associated virus) gene therapy programs, shareholders voted in early November 2026 to approve a two-step merger with Remix Therapeutics, including a reverse stock split and a rename of the combined company to Remix Therapeutics, Inc. That backdrop makes the question of whether PASG can reach a $12.50 stock price target unusually complex. Here is an evidence-based look at what that target represents and what it would take to get there.
Five identifiable, dated analyst price targets were reviewed. The most bullish is Canaccord Genuity's $23 (Buy), while Oppenheimer analyst Jay Olson carries a $15 target. The cautious end of the range includes Lucid Capital at $9, Wedbush at $8, and Chardan Capital at $7. The arithmetic mean of those five targets is roughly $12.40, rounded to a $12.50 central target. Because third-party aggregators include different target sets and dates, their displayed "analyst consensus" figures vary; the $12.50 figure here reflects the five most recent verifiable targets.
The wide $7–$23 spread tells the real story. In spring 2026, a regulatory setback and resource constraints triggered a wave of downgrades and deep cuts — Wedbush moved from $32 to $8, Lucid Capital from $68 to $9, and Chardan from $21 to $7 while shifting to a Neutral stance. TD Cowen and Guggenheim also moved to Hold/Neutral. The bullish outliers, Canaccord and Oppenheimer, frame the stock largely around the value optionality of the Remix Therapeutics combination, while the cautious names emphasize limited cash and uncertain execution.
As of mid-November 2026, PASG traded near $4.25, giving the company a market capitalization of roughly $13.7 million. The 52-week range spans $3.29 to $20.00. Reaching $12.50 from $4.25 implies about 190% upside — by any measure a very large move, not a modest drift higher. A path to that level would almost certainly require the Remix Therapeutics merger to close cleanly, the combined entity to secure meaningful financing, and investors to reprice the new pipeline's value. None of that is guaranteed.
The clearest catalyst is the merger itself. Remix Therapeutics brings a small-molecule platform targeting RNA biology, a shift from the discontinued gene therapy programs. A successful close — expected in the fourth quarter of 2026 — could attract new institutional ownership and fresh capital. Cost discipline also helps: the company reported a much narrower third-quarter loss, with adjusted EPS (earnings per share) of about -$1.47, beating consensus estimates by a wide margin as restructuring took hold. A re-rating of a newly funded, better-capitalized combined company is the core of the bullish case behind the higher analyst price targets.
The obstacles are substantial. Passage Bio generates no product revenue and reported cash and equivalents of only about $20 million at the end of September 2026, down from roughly $46 million at the end of 2025; management has cautioned that existing resources may not fund a full 12 months of operations. The merger's reverse stock split (a range of 1-for-2 to 1-for-10) will mechanically change the share count and price, and legacy Passage Bio holders are expected to own only a small single-digit percentage of the combined company — severe dilution that complicates any simple comparison of current and target prices. As a micro-cap with a low float and a wide bid-ask spread, PASG is also prone to sharp, sentiment-driven swings in either direction.
Technical context is limited but instructive. The stock sits well below its roughly $5.97 200-day moving average and near its $4.15 50-day average, reflecting a persistent long-term downtrend. The $3.29 52-week low is a key support level, while the prior $20.00 high and the psychologically important $10 and $15 levels mark resistance zones well above the current price. A sustained move toward $12.50 would first require reclaiming these higher ranges on meaningful volume.
Analyst price targets generally reflect a research horizon of roughly 12 months, but the merger resets the clock: pre-deal targets may not map cleanly onto the post-split, post-dilution share structure. Investors should watch the merger closing and its final terms, the reverse-split ratio, any concurrent financing, the combined company's cash runway, and initial Remix Therapeutics pipeline milestones. Upcoming earnings and any new analyst initiations on the merged entity will also reshape the price forecast.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like PASG, such signals can help traders surface shifting trends and manage positions more efficiently than manual chart-watching alone. Explore the AI Daily Buy/Sell Signals to see how automated analysis fits your own monitoring process.
The $12.50 central target — the mean of five analyst price targets spanning $7 to $23 — sits roughly 190% above the recent price near $4.25. It is a demanding, very large move that rests almost entirely on the successful completion of the Remix Therapeutics merger and a subsequent re-rating of the combined company. The bull case leans on the new platform and sharply reduced losses; the bear case leans on zero revenue, a shrinking cash balance, heavy dilution, and a reverse split that will redefine the share count. The wide analyst disagreement reflects genuine uncertainty, not consensus. Whether PASG approaches $12.50 will hinge on merger execution, financing, and the market's willingness to pay for an unproven pipeline — none of which can be predicted with confidence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PASG has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PASG jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To PASG | 1D Price Change % | ||
|---|---|---|---|---|
| PASG | 100% | +3.74% | ||
| AXON - PASG | 43% Loosely correlated | +2.71% | ||
| CYTK - PASG | 38% Loosely correlated | -0.05% | ||
| ARRY - PASG | 35% Loosely correlated | +0.83% | ||
| QTTB - PASG | 34% Loosely correlated | -1.25% | ||
| LXEO - PASG | 32% Poorly correlated | -1.37% | ||
More | ||||